Deep Brain Stimulation Devices Market Size 2030 - By Application, Type & Manufacturers Across North America, Europe, APAC, South America, MEA Global Market Insights recently introduced report on Global Deep Brain Stimulation Devices Market Report is an in-depth study providing complete analysis of the industry for the period 2022 to 2030. It provides complete overview of Global Deep Brain Stimulation Devices industry considering all the major industry trends, market dynamics and competitive scenario. Notably, industry players have been adopting profitable strategies to improve their business presence, enhancing the overall dynamics of the deep brain stimulation devices market. For instance, in June 2021, Bioinduction Ltd., a leading provider of DBS platform solutions, announced the successful implantation of its DBS device in patients diagnosed with Parkinson's disease. Browse key industry insights spread across 100 pages with 122 market data tables & 11 figures & charts from the report, “Deep Brain Stimulation Devices Market Analysis By Application (Parkinson's Disease, Epilepsy, Essential Tremor, Obsessive-compulsive Disorder, Dystonia, Pain Management), End-use (Hospitals, Ambulatory Surgical Centers), Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2022 – 2030” in detail along with the table of contents: https://www.gminsights.com/industry-analysis/deep-brain-stimulation-devices-market Bioinduction is credited with developing the world's first miniaturized DBS system, dubbed the Picostem. Picostem can be inserted directly into the skull, which makes it cosmetically invisible. This much smaller device eliminates the need for chest incision, extension leads, neck-tissue tunneling, and a pocket for the battery. Recently, in June 2022, a team at the Allegheny Health Network, a U.S.-based healthcare firm, announced the launch of a pivotal pilot study on the use of DBS therapy as a potential treatment method for opioid addiction. The study was planned to involve three patients with refractory OUD (opioid use disorder). Earlier, in January 2022, physicians at Allegheny Health Network joined a clinical trial to study the efficacy of DBS therapy in treating Alzheimer's disease. The earlier phases of the trial have indicated that the treatment could considerably benefit patients with mild Alzheimer's by stabilizing and enhancing their cognitive functions. In another instance, in June 2021, the Michael J. Fox Foundation presented a novel guide to assist patients with Parkinson's disease in making informed decisions about opting for DBS (deep brain stimulation) as a treatment for the motor symptoms of the disorder. © 2022 All Rights Reserved
www.gminsights.com